VaxNewMo: bioconjugating antibacterial vaccines
VaxNewMo’s platform could yield new, less costly glycoconjugate vaccines
VaxNewMo is developing a bioengineered platform that could yield inexpensive glyconjugate vaccines that prevent bacterial infections, including those not yet covered by existing vaccines.
Traditional chemical glycoconjugation is laborious and expensive, as it typically involves separate GMP processes to produce and purify the polysaccharide and the carrier protein, followed by a series of chemical reactions to link the two parts.
Compounding the problem is the antigenic diversity